Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG005 and Sorafenib in Solid Tumors
NCT03406364Phase 1Completed
- Sponsor
- Metagone Biotech Inc.
- Start
- Jun 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MG005 in solid tumor (3 cohorts), sponsored by Metagone Biotech Inc. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Dose Limiting Toxicities at 4 weeks. Started Jun 2018; status: completed.
02
Drugs
MG005
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03406364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406364.